echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > ARD: Efficacy and Safety of the Selective TYK2 Inhibitor Decavatinib in a Phase II Trial of Psoriatic Arthritis

    ARD: Efficacy and Safety of the Selective TYK2 Inhibitor Decavatinib in a Phase II Trial of Psoriatic Arthritis

    • Last Update: 2022-08-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Objective : To evaluate the efficacy and safety of the oral selective tyrosine kinase 2 (TYK2) inhibitor decavatinib in patients with active psoriatic arthritis (PsA.


    Objective To evaluate the efficacy and safety of oral selective tyrosine kinase 2 (TYK2) inhibitor decavatinib in patients with active psoriatic arthritis (PsA.


    Methods : In this double-blind phase II trial, 203 patients with PsA were randomly assigned in a 1:1:1 ratio to placebo, decavatinib 6 mg once daily, or 12 mg once dail.


    Methods In this double-blind phase II trial, 203 patients with PsA were randomly assigned in a 1:1:1 ratio to placebo, decavatinib 6 mg once daily, or 12 mg once dail.


    Results At Week 16 , ACR-20 for decavatinib 6 mg once daily (59%, p=0134) and 12 mg once daily (67%, p=0004) compared to placebo (38%) The response was significantly highe.


    CONCLUSIONS : Treatment with the selective TYK2 inhibitor decavatinib was well-tolerated and had greater effects than placebo on ACR-20 , multiple-controlled secondary endpoints, and other exploratory efficacy measures in patients with Ps.


    Mease PJ, Deodhar AA, van der Heijde D , et a.
    Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthrit.
    Annals of the Rheumatic Diseases2022; 81: 815-82 , et al Annals of the Rheumatic Diseases81: leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.